Dr. Neelaysh Vukkadala, MD

Dr. Vukkadala practices at Kapil Gupta MD a Professional Corporation in Los Angeles, California.

Dr. Vukkadala's NPI, 1003341702, was assigned on May 1, 2017. Dr. Vukkadala graduated from UCSF School of Medicine in 2017. Dr. Vukkadala holds California license A157002.

Dr. Vukkadala's primary practice is Kapil Gupta MD a Professional Corporation, at 8631 W 3rd St, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 890-2855.

Dr. Vukkadala's primary practice is Kapil Gupta MD a Professional Corporation in Los Angeles, California. Dr. Vukkadala is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vukkadala practices. Vendor and product names are available with a free account.

Otolaryngology is Dr. Vukkadala's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Vukkadala is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dr. Vukkadala is licensed in California.

Dmand AI lists upper respiratory infection (URI) among the conditions Dr. Vukkadala treats.

CMS data shows 801 Medicare services from Dr. Vukkadala across 11 procedure codes in 2024, for 309 Medicare patients. Medicare paid $109,261 for them. Every service was in an office.

CMS counts 309 Medicare patients who saw Dr. Vukkadala in 2024. The largest group is 65 to 74, with 143 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 28% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vukkadala's median patient age at 66, with 51% women.

In 2024, Dr. Vukkadala wrote 205 Medicare Part D claims for 116 patients. 100% of them were for generic drugs. CMS names the drug for 140 of them, across 6 drugs with 11 or more claims each, at $1,460 in total drug cost. In 2023, CMS named 171 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Vukkadala for performance year 2024, reported as part of a group. Dr. Vukkadala accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vukkadala as offering telehealth. CMS counts 61 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Vukkadala, more than 67% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Spinal fusion: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Vukkadala in 2021. Dr. Vukkadala's most frequent co-authors are Kara Davis Meister, MD and Tina Munjal, MD.

Dmand AI links Dr. Vukkadala to 1 clinical trial. Conditions studied include COVID-19 and Pneumonia, Viral.

CMS Open Payments shows 8 general payments to Dr. Vukkadala from 4 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Stryker Corporation paid the most, $294.

Dr. Vukkadala graduated from UCSF School of Medicine in 2017.

Dr. Vukkadala is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.